Pioneering Efficacious RNA Medicines Across Asia for Patients Faster
Uniquely positioned as the most comprehensive biopharma forum, the RNA-Based Therapeutic & Vaccine Summit Asia unites RNA leaders, innovative start-ups and solution providers to showcase new trends in RNA design leveraging artificial intelligence, novel lipid nanoparticle technologies, CMC and analytical strategic and decentralized manufacturing, covering the end-to-end of RNA drug development whilst forging new collaborative networking opportunities.
Don’t miss this opportunity to engage with the leading companies including Pfizer, Abogen Bio, Starna Therapeutics and more, making the biggest leaps in RNA therapeutic and vaccine research towards commercial markets, tailored to your needs and gaining first-hand insights to advance your RNA centric pipelines.
Hot Sessions for 2025:
Yu Pang, Senior Scientist, Pfizer
Development of Alternative Analytical Method for mRNA Product Characterization
Kee-Jong Hong, Professor, Gachon University School of Medicine & Director General, Korea mRNA Vaccine Initiative (KmVAC)
Establishing a Two-Track Strategy & Platform Technology Required for Next Pandemic Preparedness
Yeong-Chan Ahn, Business Development Director, SML Biopharm
Advancing Antibody Therapeutics Through In Vivo mRNA-LNP Delivery
Yasumasa Ota, mRNA technology Leader, Meiji Seika Pharma
Development & CMC Perspectives on the Next-Generation sa-mRNA Vaccine, KOSTAIVE
Key Benefits of Attending:
Achieve scalable process development, CMC and decentralized GMP-grade manufacturing for your RNA
development and capabilities for pandemic preparedness and commercial readiness
Unlock innovative
non-viral delivery
strategies for RNA
payloads from
LNPs to polymeric
particles with stable
formulations, sitespecific
targeting
and reduced
immunogenicity
Develop a robust
CMC and analytical
process to
effectively assess,
characterize
and release
your products
into market
with regulatory
compliance
Advance your
progress toward
the clinic with fresh data and
experience from leading Asian RNA developers focusing on in vivo CAR-T,
personalized cancer medicine and protein
replacement therapies
Harness novel
artificial intelligence
and machine
learning capabilities
to accelerate your
discovery efforts
from antigen target
identification, RNA
sequence design
and ionizable lipid
screening